MLTX
Moonlake Immunotherapeutics
NASDAQ · Biotechnology
$15.51
+0.74 (+5.01%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 207.37M | 195.61M | 178.47M |
| Net Income | -41,056,867 | -38,376,149 | -44,335,912 |
| EPS | — | — | — |
| Profit Margin | -19.8% | -19.6% | -24.8% |
| Rev Growth | +19.2% | +9.7% | +1.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 73.17M | 68.56M | 69.86M |
| Total Equity | 636.94M | 688.11M | 571.61M |
| D/E Ratio | 0.11 | 0.10 | 0.12 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -81,449,014 | -69,654,675 | -60,804,840 |
| Free Cash Flow | -45,845,658 | -33,391,408 | -32,934,200 |